Total Voting Rights

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.HUTCHMED (China) Limited 和黄医药（中国）有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 13) OVERSEAS REGULATORY ANNOUNCEMENT This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on June 28 2024.By Order of the Board Edith Shih Non-executive Director and Company Secretary Hong Kong June 28 2024 As at the date of this announcement the Directors of the Company are: Chairman and Non-executive Director: Non-executive Directors: Dr Dan ELDAR Ms Edith SHIH Ms Ling YANG Executive Directors: Dr Weiguo SU Independent Non-executive Directors: (Chief Executive Officer and Mr Paul Rutherford CARTER Chief Scientific Officer) (Senior Independent Director) Mr CHENG Chig Fung Johnny Dr Renu BHATIA (Chief Financial Officer) Mr Graeme Allan JACK Professor MOK Shu Kam TonyTotal Voting Rights Hong Kong Shanghai & Florham Park NJ — Friday June 28 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at June 28 2024 the issued share capital of HUTCHMED consisted of 871359720 ordinary shares of US$0.10 each with each share carrying one right to vote and with no shares held in treasury.The above figure of 871359720 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in or a change to their interest in HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.For illustrative purposes only the 871359720 ordinary shares would be equivalent to 871359720 depositary interests (each equating to one ordinary share) which are traded on AIM or if the depositary interests were converted in their entirety equivalent to 174271944 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.About HUTCHMED HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative commercial-stage biopharmaceutical company. ?t is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. ?t has approximately 5000 personnel across all its companies at the center of which is a team of about 1800 in oncology/immunology. Since inception HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world with its first three medicines marketed in China the first of which is also marketed in the U.S. For more information please visit: www.hutch-med.com or follow us on LinkedIn.Contacts Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries Ben Atwell / Alex Shaw FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com Zhou Yi Brunswick +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Nominated Advisor Atholl Tweedie / Freddy Crossley / +44 (20) 7886 2500 Rupert Dearden Panmure Gordon